Intrarosa Approval History
- FDA approved: Yes (First approved November 17th, 2016)
- Brand name: Intrarosa
- Generic name: prasterone
- Dosage form: Vaginal Inserts
- Company: Endoceutics Inc.
- Treatment for: Dyspareunia
Intrarosa (prasterone) is a once-daily, vaginally administered steroid indicated to treat postmenopausal women experiencing moderate to severe pain during sexual intercourse (dyspareunia) as a symptom of vulvar and vaginal atrophy.
Efficacy of Intrarosa was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women. Intrarosa was shown to reduce the severity of pain experienced during sexual intercourse when compared to placebo.
Intrarosa inserts are administered vaginally with a single-use applicator once daily at bedtime. Common side effects reported in clinical studies include vaginal discharge and abnormal Pap smear results.
Development History and FDA Approval Process for Intrarosa
|Nov 17, 2016||FDA Approves Intrarosa (prasterone) for Postmenopausal Women Experiencing Dyspareunia|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.